PE Tech Report


Like this article?

Sign up to our free newsletter

Archimed to acquire UK software co Instem for £203m

French private equity firm Archimed SAS has agreed to buy UK software company Instem, a provider of IT services for drug development in the global life sciences market, in a take-private deal that values the Staffordshire-based business at £203m. 

Archimed has agreed to pay 833 pence per share in cash, which represents a 41 per cent premium on Instem’s closing share price on Tuesday. The company’s shares jumped by 39.8 per cent, or 235p, to 825p yesterday, after news of the deal first broke.

Instem Directors were advised by Rothschild & Co and Singer Capital Markets on the acquisition.

Archimed, which is focused exclusively on investments in the healthcare sector, has more than €8bn of assets under management, having made past our current investments in 32 healthcare companies around the world.

Like this article? Sign up to our free newsletter